The Library of Congress >  Researchers >  Search Finding Aids  >  Frances Oldham Kelsey papers, 1890-2016

Frances Oldham Kelsey papers, 1890-2016

Contact UsHelpSearch All Finding Aids
Access restrictions apply.Some or all content stored offsite.
Part II: Subject File, 1902-2012 (continued)
BOX II:128 Darvon, 1979-1980 See also Container II:139, Eli Lilly and Co. Task Group
BOX II:128 Data handling of scientific information, 1959-1964, 1995-1999, undated
BOX II:128 Day, J. Edward, 1965, 1996, undated
BOX II:128 Day, Paul L., 1961, 1999, undated
BOX II:128 Definition of terms “drug” and “new drug,” undated
BOX II:128 Defoliants and herbicides See Container II:186, Pesticides and environmental hazards
BOX II:128 DeMarco, Peter See Container II:189, Procaine with polyvinylpyrrolidone (PVP)
BOX II:128 Depo-Provera, 1966, 1975-1984, undated
BOX II:128 DES (Drug), 1953, 1972-2000, undated
BOX II:128 DFMO (Drug), 2000-2001
BOX II:128 DHSM (Drug) See same container, Dihydrostreptomycin
BOX II:128 Dicumarol and related anticoagulants, 1970-1986, 1996-1997
BOX II:128 “Diet” pills, 1985, 1997-2001, undated
BOX II:128 Dietary supplements, 1982, 1998-2001, undated
BOX II:128 Diethyl glycol See Container II:139, Elixir sulfanilamide
BOX II:128 Diethylstilbestrol See same container, DES (Drug)
BOX II:128 Difluoromethyl-ornithine See same container, DFMO (Drug)
BOX II:128 Dihydrostreptomycin (DHSM), 1959, undated
BOX II:128 Dimethyl sulfoxide See Containers II:135-II:136, DMSO (Drug)
BOX II:128 Diphenylhydantoin
BOX II:128 1963-1969
BOX II:129 1970-1998, undated
(3 folders)
BOX II:129 Dithiocarb, 1963-1966, 1996, undated
BOX II:129 Diuretics, 1962-1966, 1972-1978, 1994, undated
BOX II:129 Division of Scientific Investigations, U.S. Food and Drug Administration
BOX II:129 Awards, division members, 1972-1983, undated
(3 folders)
BOX II:129 Central file, 1989-1990, 1997, undated
(1 folder)
BOX II:130 (1 folder)
BOX II:130 Clinical Investigations Branch
BOX II:130 Debarment of investigators, circa 1996
BOX II:130 Disqualified/restricted/assurance lists, 1970, 1980-1982, 1990-2000
(3 folders)
BOX II:130 General
BOX II:130 1963-1981
(3 folders)
BOX II:131 1982-1997, undated
(5 folders)
BOX II:131 Warning letters to investigators, circa 1993-1998
BOX II:131 Institutional Review Branch
BOX II:131 1972-1979
BOX II:131 1980
(1 folder)
BOX II:132 (2 folders)
BOX II:132 1981
(3 folders)
BOX II:132 1982
(1 folder)
BOX II:133 (3 folders)
BOX II:133 1983-1984, 1991, 1999, undated
(3 folders)
BOX II:133 Nonclinical Laboratory Studies Branch
BOX II:133 Good laboratory practices See Containers II:147-II:148, same heading
BOX II:133 Significant investigations prior to June 20, 1979 (Government Accounting Office request), 1987
BOX II:133 Methadone Monitoring Branch See Container II:172, Methadone monitoring
BOX II:133 Paperwork systems and procedures, 1976-1978, 1999
BOX II:134 Policies and procedures, 1973-1990, undated
(2 folders)
BOX II:134 Radioactive Drug Research Committees, 1974-1984, 1992, 1999, undated
(2 folders)
BOX II:134 Regulatory Management Branch, 1977-1991, 1999, undated
(3 folders)
BOX II:134 Speeches by division members
BOX II:134 1967, 1971-1972
BOX II:135 1980-1992, undated
(5 folders)
BOX II:135 DMSO (Drug)
BOX II:135 1963-1966
(2 folders)
BOX II:136 1980-1983, 1994-1999, undated
(3 folders)
BOX II:136 Doriden, 1962-1972, 1995, undated
BOX II:136 Dornwal, 1964, 1997, undated
BOX II:136 Drobuline, 1982-1983, 1997 See also Container II:139, Eli Lilly and Co. Task Group
BOX II:136 Drug controls, foreign
BOX II:136 1958-1987
(5 folders)
BOX II:137 1988-1993, undated
(8 folders)
BOX II:138 Drug equivalency, 1966-1971, 1982-1990, undated
BOX II:138 Drug Research Board, National Academy of Sciences, 1965-1973, 1996
(2 folders)
BOX II:138 Drugs and deformities
BOX II:138 1960-1987
(4 folders)
BOX II:139 1990-2000, undated
BOX II:139 Dusheiko, Geoffrey M., 1994-1996
BOX II:139 Edgewood Arsenal, Edgewood, Md., site visit, 1965, 1972-1975, 1997
BOX II:139 Efficacy guidelines See Container II:148, Guidance for Industry: Providing Adequate Clinical Evidence of Effectiveness , draft
BOX II:139 Eflornithine See Container II:128, DFMO (Drug)
BOX II:139 Eli Lilly and Co. Task Group See also Container II:100, Benoxaprofen ; Container II:128, Darvon ; Container II:136, Drobuline
BOX II:139 General, 1980-1981
BOX II:139 Report, 1983
(2 folders)
BOX II:139 Elixir sulfanilamide, 1967, 1983, circa 1993, 2002
BOX II:139 Ellenhorn, Matthew J., 1963, circa 1966, 1996-1999
BOX II:140 Enzymes, 1960-1962, 1996
BOX II:140 Epidemiology, 1962-1988, undated
(3 folders)
BOX II:140 Establishment Evaluation System
BOX II:140 Division of Scientific Investigations, flow charts and milestones, circa 1995-circa 1996
BOX II:140 General, 1995-1996
BOX II:140 Ethical consideration
BOX II:140 1965-1979
(2 folders)
BOX II:141 1980-1999, undated
BOX II:141 Ethical criteria, 1960-2001, undated
(5 folders)
BOX II:141 European Teratology Society, 1971-1977, 1994-2000
(2 folders)
BOX II:142 Executive Women in Government, 1994-1996
BOX II:142 Exempt drugs, 1979
BOX II:142 FDA Distinguished Alumni/Professor Emeritus Policy Task Force, 1998
BOX II:142 Federal Executive Professional Association, 1979-1986, 1998
BOX II:142 Feldene (piroxicam), 1983-1986
BOX II:142 Fetus and newborn, miscellaneous, 1961-1979, 1985-1986, undated
(2 folders)
BOX II:142 Fialuridine (FIAU), 1993-1994, 2001
BOX II:142 Flunixin, 1976-1977
BOX II:142 Folic acid, memorandum to John Patrick Swann with attachments, 1951-1952, 1963, 1995, undated
BOX II:143 Foreign clinical studies, U.S. Food and Drug Administration policy, 1973-1992, undated
(3 folders)
BOX II:143 Foreign travel requests, 1978-1982
Next Page »

Contents List